XNApharma GmbH
Dr. Tobias Pöhlmann
Ronneburger Straße 74
07546 Gera
Dr. Tobias Pöhlmann
Ronneburger Straße 74
07546 Gera
info@xnapharma.com
https://xnapharma.com
Patents
XNApharma patent portfolio
XNApharma shares the following patent portfolio with the Friedrich-Schiller-University of Jena, Germany. Our patents are administered by the patent law firm Vossius and Partner, Munich Germany.
| Biologically active molecules, particulary based on PNA and siRNA, method for the cell-specific activation thereof, and application kit to be administered | EP 2121922B1 CA 2678044C DE 102007008596B4 US 9347060B2 |
| Cell specifically effective molecules on the basis of siRNA and application kits for the production thereof and use thereof | DE 102009043743B4 US 9315808B2 |
| Cell specific activatable biologically active molecules on the basis of siRNA, method for activation, and application kit | AKZ 10 2010 022 937 |
| Biologically active molecules for influencing virus-, bacteria-, parasite-infected cells and/or tumor cells and method for the use thereof | AKZ 10 2010 004 957 WO 2011 / 085720 |
| Biologically active nucleotide molecules for selectively killing of cells, use thereof, and application kit | AKZ 10 2011 009 470 WO 2012 09823 |
| New cell specifically active nucleotide molecules and application kit for the use thereof | AKZ 10 2012 022 596 PCT/EP/2013/073887 |
| Interfering nucleotide molecules for the targeted cell death, method of use thereof and application kit | AKZ 10 2013 003 869 PCT/EP2014/053666 |
© XNApharma GmbH, Ronneburger Straße 74, 07546 Gera
Source: https://xnapharma.com/Patents
Copyright© XNApharma GmbH
